Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G007-LK is a potent and selective small-molecule inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2). It functions by binding to the adenosine pocket of the tankyrase PARP domain, which prevents the poly-ADP-ribosylation of AXIN proteins. This stabilization of AXIN leads to the degradation of β-catenin, thereby inhibiting the WNT/β-catenin signaling pathway. G007-LK also modulates YAP signaling. Preclinical research indicates that G007-LK can overcome resistance to immune checkpoint inhibitors, such as anti-PD-1 antibodies, in melanoma by promoting T-cell infiltration and enhancing the anti-tumor immune microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on G007-LK.